These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32248674)

  • 1. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.
    İskender G; İskender D; Ertek M
    Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
    Molica S; Baumann T; Giannarelli D
    Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
    [No Abstract]   [Full Text] [Related]  

  • 3. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
    Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V
    Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543
    [No Abstract]   [Full Text] [Related]  

  • 4. Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.
    Molica S; Giannarelli D; Baumann T; Montserrat E
    Eur J Haematol; 2020 May; 104(5):512-515. PubMed ID: 31957067
    [No Abstract]   [Full Text] [Related]  

  • 5. Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.
    Kidoguchi K; Kubato Y; Nishimura Y; Kizuka-Sano H; Kimura S
    Turk J Haematol; 2021 Feb; 38(1):83-85. PubMed ID: 33161683
    [No Abstract]   [Full Text] [Related]  

  • 6. Ibrutinib-Induced Skin Rash.
    Kirar S; Gogia A; Gupta R; Mallick S
    Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
    [No Abstract]   [Full Text] [Related]  

  • 7. Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation.
    Yang S; Zhu R; Li N; Feng Y; Zuo R; Gale RP; Huang X
    Acta Haematol; 2022; 145(1):54-62. PubMed ID: 34569486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
    Ozbagcivan O; Akarsu S; Nazli EC; Lebe B; Fetil E
    Ann Hematol; 2021 Jan; 100(1):293-294. PubMed ID: 32221651
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.
    Aarup K; Rotbain EC; Enggaard L; Pedersen RS; Bergmann OJ; Thomsen RH; Frederiksen M; Frederiksen H; Nielsen T; Christiansen I; Andersen MA; Niemann CU
    Eur J Haematol; 2020 Nov; 105(5):646-654. PubMed ID: 32736410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
    Molica S; Gianfelici V; Levato L
    Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.
    Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P;
    Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overall survival benefit of symptom monitoring in real-world patients with chronic lymphocytic leukaemia treated with ibrutinib: a FiLO group study.
    Ysebaert L; Quinquenel A; Bijou F; Ferrant E; Michallet AS;
    Eur J Cancer; 2020 Aug; 135():170-172. PubMed ID: 32585590
    [No Abstract]   [Full Text] [Related]  

  • 13. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.
    Niemann CU; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Kater AP
    Blood; 2021 Feb; 137(8):1117-1120. PubMed ID: 33027809
    [No Abstract]   [Full Text] [Related]  

  • 14. Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies:
    Brown JR; Ghia P; Jurczak W; Kahl BS; Lamanna N; Robak T; Shadman M; Tam CS; Qiu L; Paik J; Salmi T; Wang L; Zhang J; Zhang M; Cohen A; Ma H; Tedeschi A
    Haematologica; 2024 Jul; 109(7):2277-2283. PubMed ID: 38426293
    [No Abstract]   [Full Text] [Related]  

  • 15. Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.
    Martín-Moro F; García-Cosío M; Marquet-Palomanes J; López-Gutiérrez M; Pian-Arias H; López-Jiménez FJ
    Ann Hematol; 2022 Jan; 101(1):213-215. PubMed ID: 33423076
    [No Abstract]   [Full Text] [Related]  

  • 16. The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia.
    Gianfelici V; Levato L; Molica S
    Curr Hematol Malig Rep; 2020 Aug; 15(4):343-349. PubMed ID: 32500413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
    Langerbeins P; Zhang C; Robrecht S; Cramer P; Fürstenau M; Al-Sawaf O; von Tresckow J; Fink AM; Kreuzer KA; Vehling-Kaiser U; Tausch E; Müller L; Eckart MJ; Schlag R; Freier W; Gaska T; Balser C; Reiser M; Stauch M; Wendtner CM; Fischer K; Stilgenbauer S; Eichhorst B; Hallek M
    Blood; 2022 Jan; 139(2):177-187. PubMed ID: 34758069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib dose modifications in the management of CLL.
    Hardy-Abeloos C; Pinotti R; Gabrilove J
    J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
    Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK
    Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia.
    Orlandi EM; Elena C; Bono E
    Leuk Lymphoma; 2017 Jul; 58(7):1764-1766. PubMed ID: 27892750
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.